Debjit Chattopadhyay
Stock Analyst at Guggenheim
(3.42)
# 955
Out of 4,711 analysts
74
Total ratings
50.77%
Success rate
3.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Reiterates: Buy | n/a | $16.98 | - | 5 | Dec 11, 2024 | |
| PRME Prime Medicine | Reiterates: Buy | $18 | $2.90 | +520.69% | 3 | Dec 3, 2024 | |
| BNTC Benitec Biopharma | Reiterates: Buy | $17 | $11.41 | +48.99% | 2 | Dec 3, 2024 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $24 → $28 | $17.16 | +63.17% | 4 | Nov 15, 2024 | |
| FOLD Amicus Therapeutics | Maintains: Buy | $13 → $15 | $9.80 | +53.06% | 2 | Nov 7, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $70 → $65 | $35.63 | +82.43% | 3 | Oct 9, 2024 | |
| RZLT Rezolute | Initiates: Buy | $11 | $4.39 | +150.57% | 1 | Aug 27, 2024 | |
| DYN Dyne Therapeutics | Maintains: Buy | $45 → $50 | $23.99 | +108.42% | 3 | Aug 15, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $450 → $558 | $397.27 | +40.46% | 7 | Aug 2, 2024 | |
| CRSP CRISPR Therapeutics AG | Assumes: Neutral | n/a | $40.72 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $4.72 | +302.54% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $5.75 | +282.61% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $175 | $164.83 | +6.17% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $25.50 | +17.65% | 1 | Jan 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $40 | $45.18 | -11.47% | 1 | Nov 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $110 | $65.66 | +67.53% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $1.87 | +1,450.80% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $11 | $0.66 | +1,566.67% | 2 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $50 | $44.22 | +13.07% | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $245.44 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $130 | $29.01 | +348.12% | 1 | Jan 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $1.85 | +1,413.51% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $170 | $12.18 | +1,295.73% | 1 | Oct 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $13.51 | +48.04% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $221 | $118.97 | +85.76% | 4 | Aug 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $26.76 | +359.64% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $14.14 | +281.90% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $2.59 | +2,216.60% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $35.42 | - | 3 | Jun 26, 2017 |
uniQure
Dec 11, 2024
Reiterates: Buy
Price Target: n/a
Current: $16.98
Upside: -
Prime Medicine
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $2.90
Upside: +520.69%
Benitec Biopharma
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $11.41
Upside: +48.99%
Centessa Pharmaceuticals
Nov 15, 2024
Maintains: Buy
Price Target: $24 → $28
Current: $17.16
Upside: +63.17%
Amicus Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $9.80
Upside: +53.06%
Ionis Pharmaceuticals
Oct 9, 2024
Maintains: Buy
Price Target: $70 → $65
Current: $35.63
Upside: +82.43%
Rezolute
Aug 27, 2024
Initiates: Buy
Price Target: $11
Current: $4.39
Upside: +150.57%
Dyne Therapeutics
Aug 15, 2024
Maintains: Buy
Price Target: $45 → $50
Current: $23.99
Upside: +108.42%
Vertex Pharmaceuticals
Aug 2, 2024
Maintains: Buy
Price Target: $450 → $558
Current: $397.27
Upside: +40.46%
CRISPR Therapeutics AG
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $40.72
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $4.72
Upside: +302.54%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $5.75
Upside: +282.61%
Feb 27, 2024
Maintains: Buy
Price Target: $130 → $175
Current: $164.83
Upside: +6.17%
Jan 18, 2024
Initiates: Buy
Price Target: $30
Current: $25.50
Upside: +17.65%
Nov 21, 2023
Assumes: Buy
Price Target: $40
Current: $45.18
Upside: -11.47%
Sep 13, 2023
Reiterates: Buy
Price Target: $110
Current: $65.66
Upside: +67.53%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $1.87
Upside: +1,450.80%
Nov 11, 2022
Maintains: Buy
Price Target: $13 → $11
Current: $0.66
Upside: +1,566.67%
Oct 13, 2022
Upgrades: Buy
Price Target: $50
Current: $44.22
Upside: +13.07%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $245.44
Upside: -
Jan 5, 2022
Initiates: Buy
Price Target: $130
Current: $29.01
Upside: +348.12%
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $1.85
Upside: +1,413.51%
Oct 5, 2021
Initiates: Buy
Price Target: $170
Current: $12.18
Upside: +1,295.73%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $13.51
Upside: +48.04%
Aug 31, 2020
Maintains: Buy
Price Target: $260 → $221
Current: $118.97
Upside: +85.76%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $26.76
Upside: +359.64%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $14.14
Upside: +281.90%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $2.59
Upside: +2,216.60%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $35.42
Upside: -